Results 291 to 300 of about 564,426 (377)
Treatment outcomes of ABVD in classical Hodgkin lymphoma patients from Thailand without procarbazine access. [PDF]
Suttantapidok S+2 more
europepmc +1 more source
Optic Neuropathy and Central Retinal Artery Occlusion in Non-Hodgkin Lymphoma
Anna Fierz+2 more
openalex +1 more source
Mohammed Al-Hamadani+5 more
semanticscholar +1 more source
Gaucher disease, state of the art and perspectives
Abstract Knowledge about Gaucher disease (GD), considered a model for rare diseases, has considerably increased since its discovery. The pathophysiology of this lysosomal disorder is better known, and specific therapies that can control many aspects of the disease have been developed, particularly for the most common form, Type 1 GD.
Fabrice Camou, Marc G. Berger
wiley +1 more source
Cytomegalovirus Lymphadenitis Mimicking Hodgkin Lymphoma Relapse. [PDF]
Cagdas BM+3 more
europepmc +1 more source
The Dental Status of Patients Taking Common Biologic Agents: A Single‐Center Cross‐Sectional Study
ABSTRACT Objectives Despite expanding use and medical applications, little is known about the impact of biologic agents (BAs) on dental treatment. The aim of this study was to investigate the dental status of patients on common classes of BAs to understand treatment needs and use in this population.
Shivani Shah+4 more
wiley +1 more source
Impact of Time-to-Treatment Initiation and First Inter-Cycle Delay in Patients with Hodgkin Lymphoma. [PDF]
Donmez D+4 more
europepmc +1 more source
Abstract Orthotopic allograft transplantation (OAT) is a significant approach to addressing organ failure. However, persistent immune responses to the allograft affect chronic rejection, which induces OAT vasculopathy (OATV) and organ failure. Porphyromonas gingivalis can infiltrate remote organs via the bloodstream, thereby intensifying the severity ...
Chien‐Sung Tsai+7 more
wiley +1 more source
Hodgkin lymphoma presenting as paraneoplastic cerebellar degeneration: A case report. [PDF]
Kadubandi A+2 more
europepmc +1 more source